Personalis (PSNL) Set to Announce Earnings on Wednesday

Personalis (NASDAQ:PSNL) will be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Personalis to post earnings of ($0.33) per share for the quarter. Personalis has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that wish to listen to the company’s earnings conference call can do so using this link.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The business had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. During the same period last year, the business earned ($0.50) EPS. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Stock Performance

Shares of PSNL stock opened at $5.13 on Wednesday. The stock’s 50 day simple moving average is $5.25 and its 200 day simple moving average is $3.15. Personalis has a twelve month low of $0.89 and a twelve month high of $7.20. The company has a market capitalization of $266.45 million, a price-to-earnings ratio of -2.70 and a beta of 1.92.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HC Wainwright raised their target price on Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a report on Monday, August 19th. BTIG Research raised their target price on Personalis from $5.50 to $7.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Needham & Company LLC raised their target price on Personalis from $5.50 to $7.25 and gave the company a “buy” rating in a report on Friday, August 16th.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.